JP7629228B2 - Ａｌｋ陰性癌および形質細胞媒介性疾患の治療のためのａｌｋ阻害剤 - Google Patents

Ａｌｋ陰性癌および形質細胞媒介性疾患の治療のためのａｌｋ阻害剤 Download PDF

Info

Publication number
JP7629228B2
JP7629228B2 JP2022525050A JP2022525050A JP7629228B2 JP 7629228 B2 JP7629228 B2 JP 7629228B2 JP 2022525050 A JP2022525050 A JP 2022525050A JP 2022525050 A JP2022525050 A JP 2022525050A JP 7629228 B2 JP7629228 B2 JP 7629228B2
Authority
JP
Japan
Prior art keywords
alk
cells
ltk
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554258A (ja
JP2022554258A5 (https=
Inventor
ファルハン、ヘッソ
ムンテ、ルズヴィ
タスケン、チェーティル
スコンランド、シグリッド
ジリベルト、マリアセレナ
シュイェスヴォルド、フレドリック ヘレム
ドリーセン、クリストフ
ベス、レンカ
ベス、アンドレイ
Original Assignee
ウニヴァーシテテット イ オスロ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニヴァーシテテット イ オスロ filed Critical ウニヴァーシテテット イ オスロ
Publication of JP2022554258A publication Critical patent/JP2022554258A/ja
Publication of JP2022554258A5 publication Critical patent/JP2022554258A5/ja
Application granted granted Critical
Publication of JP7629228B2 publication Critical patent/JP7629228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022525050A 2019-10-28 2020-03-12 Ａｌｋ陰性癌および形質細胞媒介性疾患の治療のためのａｌｋ阻害剤 Active JP7629228B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201915618A GB201915618D0 (en) 2019-10-28 2019-10-28 ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
GB1915618.1 2019-10-28
PCT/EP2020/056698 WO2021083555A1 (en) 2019-10-28 2020-03-12 Alk inhibitors for treatment of alk-negative cancer and plasma cell-mediated diseases

Publications (3)

Publication Number Publication Date
JP2022554258A JP2022554258A (ja) 2022-12-28
JP2022554258A5 JP2022554258A5 (https=) 2023-03-15
JP7629228B2 true JP7629228B2 (ja) 2025-02-13

Family

ID=68768829

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525050A Active JP7629228B2 (ja) 2019-10-28 2020-03-12 Ａｌｋ陰性癌および形質細胞媒介性疾患の治療のためのａｌｋ阻害剤

Country Status (9)

Country Link
US (1) US12465607B2 (https=)
EP (1) EP4051288A1 (https=)
JP (1) JP7629228B2 (https=)
KR (1) KR102946955B1 (https=)
CN (1) CN114901289A (https=)
AU (1) AU2020374150B2 (https=)
CA (1) CA3159339A1 (https=)
GB (1) GB201915618D0 (https=)
WO (1) WO2021083555A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230091284A (ko) * 2021-12-16 2023-06-23 부산대학교 산학협력단 Surf4 억제제를 포함하는 혈액암의 예방 또는 치료용 약학적 조성물
WO2024017334A1 (zh) * 2022-07-22 2024-01-25 贝达药业股份有限公司 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
CN115993453B (zh) * 2022-07-22 2025-03-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024059525A2 (en) * 2022-09-12 2024-03-21 Endotarget, Inc. Compounds and methods for the targeted degradation of anaplastic lymphoma kinase and ros1 kinase
KR20250160958A (ko) * 2023-03-22 2025-11-14 어센테지 파마 (쑤저우) 컴퍼니 리미티드 약학적 조합 및 이의 응용
CN119700981A (zh) * 2024-12-24 2025-03-28 中南大学湘雅二医院 Alk/ltk抑制剂在制备治疗和/或预防慢性淋巴细胞白血病的产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512329A (ja) 2006-12-08 2010-04-22 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP2011526284A (ja) 2008-06-25 2011-10-06 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としてのピリミジン誘導体
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2019141235A1 (zh) 2018-01-20 2019-07-25 中国科学院上海药物研究所 治疗肝癌的药物组合和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009233963B2 (en) 2008-04-07 2011-10-06 Irm Llc Compounds and compositions as kinase inhibitors
US8904383B2 (en) 2008-04-10 2014-12-02 Hewlett-Packard Development Company, L.P. Virtual machine migration according to environmental data
BR112013015000A2 (pt) 2010-12-17 2016-08-09 Novartis Ag formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
EP2916841A1 (en) 2012-11-07 2015-09-16 Novartis AG Combination therapy
US10117872B2 (en) 2014-03-28 2018-11-06 Università Degli Studi Di Genova Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
CN105294649B (zh) 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
KR20170060042A (ko) * 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
JPWO2019039390A1 (ja) 2017-08-25 2020-07-30 国立大学法人東海国立大学機構 若年性骨髄単球性白血病治療薬
WO2019113345A1 (en) 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512329A (ja) 2006-12-08 2010-04-22 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP2011526284A (ja) 2008-06-25 2011-10-06 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としてのピリミジン誘導体
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2019141235A1 (zh) 2018-01-20 2019-07-25 中国科学院上海药物研究所 治疗肝癌的药物组合和方法

Also Published As

Publication number Publication date
KR102946955B1 (ko) 2026-04-02
CA3159339A1 (en) 2021-05-06
JP2022554258A (ja) 2022-12-28
GB201915618D0 (en) 2019-12-11
WO2021083555A1 (en) 2021-05-06
EP4051288A1 (en) 2022-09-07
CN114901289A (zh) 2022-08-12
US20220401444A1 (en) 2022-12-22
AU2020374150B2 (en) 2025-12-18
US12465607B2 (en) 2025-11-11
KR20220098158A (ko) 2022-07-11
AU2020374150A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP7629228B2 (ja) Ａｌｋ陰性癌および形質細胞媒介性疾患の治療のためのａｌｋ阻害剤
Bhansali et al. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
Ren Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia
Hurtz et al. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
US9168257B2 (en) Combination therapy for MDS
Wang et al. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia
Mizukawa et al. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia
Appelmann et al. Janus kinase inhibition by ruxolitinib extends dasatinib-and dexamethasone-induced remissions in a mouse model of Ph+ ALL
US10130590B2 (en) Methods of treating cancer with atovaquone-related compounds
De Vries et al. Tyrosine kinase 2 signalling drives pathogenic T cells in colitis
Rampal et al. Therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms
TW202021626A (zh) 辨識有可能受益於以端粒酶抑制劑治療之患者的方法
JP2007526882A (ja) リンパ球性白血病を治療するためのロスコビチンの使用
Wen et al. Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease
Kannan et al. Antileukemia effects of notch-mediated inhibition of oncogenic PLK1 in B-cell acute lymphoblastic leukemia
JP6768232B2 (ja) 慢性骨髄性白血病癌幹細胞の成長抑制用または増殖抑制用の組成物、及びそのスクリーニング方法
KR20150131155A (ko) 종양 약역학적 반응의 바이오마커
WO2015134603A2 (en) Methods for treating cancer
JP7684910B2 (ja) 小児対象において神経膠腫を治療するためのｔｇ０２の使用
Gu et al. HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway
JP7759032B2 (ja) 脳血管攣縮抑制剤
Wodi Targeting the Splice Factor Kinases SRPK1 and CLK1 in Leukaemia
Bandini FUNCTIONAL GENOMIC APPROACHES TO SENSITIZE HEMATOLOGICAL MALIGNANCIES TO PROTEASOME INHIBITORS
Agarwal et al. G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent
Cheung The isolation and characterisation of novel small molecule inhibitors of the MYCN transcriptional pathway for the potential treatment of childhood neuroblastoma

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20220722

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20220721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250124

R150 Certificate of patent or registration of utility model

Ref document number: 7629228

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150